Pharming Group N.V. announced on September 26, 2024, that it received marketing authorization in the U.K. for Joenja® (leniolisib), the first treatment for activated PI3Kδ syndrome (APDS) for patients aged 12 and older. This marks Pharming's third country approval for this rare disease, highlighting significant progress in offering targeted therapies for patients.